IP Library Granted Patent US 11,191,845
Granted Patent B2
US 11,191,845 · App. 16/013,828 · Granted Dec 7, 2021

CD38 antibody drug conjugate

Inventors: Tong Zhu (San Diego, CA); Alisher Khasanov (San Diego, CA); Gang Chen (San Diego, CA); Katherine Fells (San Diego, CA); Heyue Zhou (San Diego, CA); John Dixon Gray (San Diego, CA)
Assignee: Sorrento Therapeutics, Inc.
A61K47/6871A61K31/704A61K38/07A61K38/08A61K47/6803A61K47/6809A61K47/6817A61K47/6849A61P35/00C07K16/2896C07K16/40A61K2039/505C07K2317/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,191,845
App. No.
16/013,828
Granted
Dec 7, 2021
Kind
B2
Abstract

There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.

Claims (21)

1. An antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to CD38, a linker moiety conjugated to a Cys residue in a hinge region of an IgG antibody, wherein the IgG antibody comprises a heavy chain mutated such that the hinge region contains only one Cys residue, wherein the ADC is chosen from

2. The ADC composition of claim 1 , wherein the ADC is

3. The ADC composition of claim 1 , wherein the ADC is

4. The ADC composition of claim 1 , wherein the ADC is

5. The ADC composition of claim 1 , wherein the ADC is

6. The ADC composition of claim 1 , wherein the ADC is

7. The ADC composition of claim 1 , wherein the ADC is

8. An anti-CD38 ADC composition comprising:

(a) an anti-CD38 IgG antibody comprising a heavy chain variable region comprising the sequence of SEQ ID NO. 1 and a light chain variable region comprising the sequence of SEQ ID NO. 2 or 3;

(b) a conjugation linker moiety, wherein the conjugation linker comprises a linker and a conjugation moiety which covalently binds to a single Cys residue in a hinge region of an IgG antibody, and

wherein the anti-CD38 ADC is chosen from:

wherein Ab is the anti-CD38 IgG antibody.

9. The ADC composition of claim 8 , wherein the ADC is

10. The ADC composition of claim 8 , wherein the ADC is

11. The ADC composition of claim 8 , wherein the ADC is

12. The ADC composition of claim 8 , wherein the ADC is

13. The ADC composition of claim 8 , wherein the ADC is

14. The ADC composition of claim 8 , wherein the ADC is

15. The ADC composition of claim 8 , wherein the heavy chain hinge region of the IgG antibody is mutated such that the heavy chain hinge region contains only one Cys residue.

16. A compound selected from:

or a pharmaceutically acceptable salt thereof.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2024
From: SORRENTO THERAPEUTICS, INC.
To: VIVASOR, INC.
Reel/Frame 067529/0019 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: ZHU, TONG; KHASANOV, ALISHER; FELLS, KATHERINE; CHEN, GANG; ZHOU, HEYUE; GRAY, JOHN DIXON
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 056378/0383 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →